Details for Patent: 7,022,713
✉ Email this page to a colleague
Which drugs does patent 7,022,713 protect, and when does it expire?
Patent 7,022,713 protects LIVALO and is included in one NDA.
Protection for LIVALO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has seventeen patent family members in fourteen countries.
Summary for Patent: 7,022,713
| Title: | Hyperlipemia therapeutic agent |
| Abstract: | The present invention relates to a hyperlipemia therapeutic agent comprising pitavastatins and eicosapentaenoic acid or an ester derivative thereof as effective ingredients.According to the present invention, a type IIb and type IV hyperlipemia therapeutic agent having an excellent effect of lowering the cholesterol and triglyceride in blood is provided. |
| Inventor(s): | Aoki; Taro (Tokorozawa, JP), Yamaguchi; Junji (Higashimurayama, JP), Sasaki; Yusuke (Higashimurayama, JP) |
| Assignee: | KOWA Co., Ltd. (Nagoya, JP) Nissan Chemical Industries, Ltd. (Tokyo, JP) |
| Application Number: | 10/780,640 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,022,713 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 7,022,713
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kowa Co | LIVALO | pitavastatin calcium | TABLET;ORAL | 022363-001 | Aug 3, 2009 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Kowa Co | LIVALO | pitavastatin calcium | TABLET;ORAL | 022363-002 | Aug 3, 2009 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Kowa Co | LIVALO | pitavastatin calcium | TABLET;ORAL | 022363-003 | Aug 3, 2009 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
